CN101641111A - 包含用于治疗肥胖症的菜蓟与菜豆提取物的制剂 - Google Patents
包含用于治疗肥胖症的菜蓟与菜豆提取物的制剂 Download PDFInfo
- Publication number
- CN101641111A CN101641111A CN200880007206A CN200880007206A CN101641111A CN 101641111 A CN101641111 A CN 101641111A CN 200880007206 A CN200880007206 A CN 200880007206A CN 200880007206 A CN200880007206 A CN 200880007206A CN 101641111 A CN101641111 A CN 101641111A
- Authority
- CN
- China
- Prior art keywords
- extract
- cynara scolymus
- semen phaseoli
- cyhara cardunculus
- useful
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000284 extract Substances 0.000 title claims abstract description 68
- 244000019459 Cynara cardunculus Species 0.000 title claims abstract description 31
- 235000019106 Cynara scolymus Nutrition 0.000 title claims abstract description 31
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- 244000046052 Phaseolus vulgaris Species 0.000 title abstract description 7
- 208000008589 Obesity Diseases 0.000 title abstract description 5
- 235000020824 obesity Nutrition 0.000 title abstract description 5
- 235000010627 Phaseolus vulgaris Nutrition 0.000 title abstract description 3
- 238000009472 formulation Methods 0.000 title description 2
- 239000002253 acid Substances 0.000 claims abstract description 8
- 239000008280 blood Substances 0.000 claims abstract description 5
- 210000004369 blood Anatomy 0.000 claims abstract description 5
- 210000000582 semen Anatomy 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 11
- 108010047620 Phytohemagglutinins Proteins 0.000 claims description 5
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 5
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 claims description 5
- 235000009498 luteolin Nutrition 0.000 claims description 5
- -1 luteolin glucosides Chemical class 0.000 claims description 5
- 230000001885 phytohemagglutinin Effects 0.000 claims description 5
- 239000003392 amylase inhibitor Substances 0.000 claims description 4
- 229930182478 glucoside Natural products 0.000 claims description 4
- 101710171801 Alpha-amylase inhibitor Proteins 0.000 claims description 3
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 239000003921 oil Substances 0.000 abstract description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 6
- 239000008103 glucose Substances 0.000 abstract description 6
- 235000019789 appetite Nutrition 0.000 abstract description 4
- 230000036528 appetite Effects 0.000 abstract description 4
- 235000012000 cholesterol Nutrition 0.000 abstract description 3
- 240000008916 Oenothera biennis Species 0.000 abstract description 2
- 235000004496 Oenothera biennis Nutrition 0.000 abstract description 2
- 150000007513 acids Chemical class 0.000 abstract description 2
- 230000037396 body weight Effects 0.000 abstract description 2
- 229940045761 evening primrose extract Drugs 0.000 abstract description 2
- 235000008524 evening primrose extract Nutrition 0.000 abstract description 2
- 235000012054 meals Nutrition 0.000 abstract description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 235000019198 oils Nutrition 0.000 abstract 2
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 235000021323 fish oil Nutrition 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 229940012843 omega-3 fatty acid Drugs 0.000 abstract 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 abstract 1
- 239000006014 omega-3 oil Substances 0.000 abstract 1
- 230000001235 sensitizing effect Effects 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000000463 material Substances 0.000 description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000008108 microcrystalline cellulose Substances 0.000 description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 6
- 239000008187 granular material Substances 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 240000001789 Carlina acaulis Species 0.000 description 3
- 235000005882 Carlina acaulis Nutrition 0.000 description 3
- 102100025841 Cholecystokinin Human genes 0.000 description 3
- 101800001982 Cholecystokinin Proteins 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229940107137 cholecystokinin Drugs 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 239000002028 Biomass Substances 0.000 description 2
- YDDUMTOHNYZQPO-RVXRWRFUSA-N Cynarine Chemical compound O([C@@H]1C[C@@](C[C@H]([C@@H]1O)O)(OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDUMTOHNYZQPO-RVXRWRFUSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229950009125 cynarine Drugs 0.000 description 2
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 229940083037 simethicone Drugs 0.000 description 2
- 229940083466 soybean lecithin Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000001069 triethyl citrate Substances 0.000 description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 2
- 235000013769 triethyl citrate Nutrition 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229940122816 Amylase inhibitor Drugs 0.000 description 1
- 235000003198 Cynara Nutrition 0.000 description 1
- 241000208947 Cynara Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 241000219833 Phaseolus Species 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000021407 appetite control Nutrition 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001989 choleretic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000012622 synthetic inhibitor Substances 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及具有高含量的咖啡鞣酸的菜蓟提取物和包含所述菜蓟提取物与菜豆提取物的组合物。所述组合物用于降低肥胖，这是由于其通过使细胞对胰岛素敏感而降低胆固醇、甘油三酯和血糖。该组合在饭前服用时降低食欲，从而导致体重减轻。所述提取物优选在月见草油、鱼油或富含不饱和的ω－3脂肪酸的油中配制。
Description
发明领域
本发明涉及包含菜蓟(Cynara Scolymus)提取物(优选具有高含量的咖啡鞣酸)和菜豆(Phaseolus vulgaris)提取物的制剂，其比例为1∶0.25到1∶1。
该组合物用于降低肥胖，因为它降低胆固醇、甘油三酯、血糖和食欲。
发明背景
肥胖症是当前的重要健康问题之一，特别是在工业化国家中，它具有在心循环方面和骨骼方面的严重后果。
碳水化合物是热量的重要来源，并且促进易患肥胖症和II型糖尿病的个体中的脂肪合成。由于高血糖导致能量储存增加，所以能降低生物可利用的葡萄糖的物质的可用性非常重要。因为淀粉是葡萄糖的主要来源，所以对从植物原料中获得的或者合成的特异性的α-葡萄糖苷酶和α-淀粉酶抑制剂进行了研究。长期以来，人们已经知道某些种子和果肉(pulses)含有这样的物质，其在没有完全煮熟前就食用，可能会产生不良作用。许多果肉含有蛋白酶抑制剂、淀粉酶抑制剂和通过降低食欲而阻止食用者继续食用它们的物质。这些物质被称为植物凝集素，在高剂量下能引起胰腺增生，但是在较低剂量下可以用于控制食欲。
在高剂量下，这些植物凝集素避开了肠的转运并结合肠上皮细胞，在此它们引起胆囊收缩素的分泌，胆囊收缩素是一种刺激胰腺分泌并继而造成其扩张的促激素。胆囊收缩素也具有有利的作用，因为它可通过降低胃运动而减少食欲。
从文献中已知，菜蓟的水提取物或含水的醇提取物具有降低血胆固醇、促进胆汁分泌和抗消化不良的活性。这种降低血胆固醇的活性已被报道了多年，其与两类物质有关：菜蓟素，一种二咖啡酰奎宁酸；和衍生自四羟黄酮的黄酮类化合物，其已被证实在体外抑制肝的胆固醇合成。部分活性与菜蓟提取物特异性的促胆汁分泌的作用有关。菜蓟的提取方法在WO2007/006391中进行了描述。
发明描述
现已发现，将菜蓟提取物和菜豆提取物组合，可获得令人惊讶的减轻体重的效果，该效果与所施用的剂量成比例；在大鼠中的数据表明体重减轻的效果不是简单地与降低血糖水平有关，而且与食物消耗的明确降低有关。各种药理学的实验证明：即使不限制食物的摄入，这种食物摄取的降低也与简单的毒性效应无关，而是与改变进食欲望有关。
朝鲜蓟提取物(其通过改变肠与肝脏内的葡萄糖转运来帮助加强脂肪和葡萄糖的清除)和降低淀粉代谢的物质的组合，在维持体重和阻止体重增加中特别重要。
发明详述
根据本发明的可利用的提取物是商品化的朝鲜蓟提取物、根据WO2007/006391的提取物、或是具有高含量的咖啡鞣酸和四羟黄酮糖苷的朝鲜蓟提取物，所述的最后一种提取物是从未干燥的可食用的花头(heads)中用C1-C3醇或其与水的混合物进行提取而得到的。
从未干燥的可食用的菜蓟花头中进行的提取优选使用乙醇或乙醇/水混合物，尤其是使用7∶3v/v比例的乙醇/水。在纯化后，获得的提取物由于其高含量的咖啡鞣酸和以四羟黄酮糖苷表示的黄酮类而不同于已知的提取物。该提取物也具有降血糖的活性。该提取物可以从多种菜蓟品种，优选刺状变种(spiny variety)，甚至更优选撒丁刺状变种(Sardinian spinyvariety)中制备。
优选的菜蓟提取物含有的咖啡鞣酸量为30-60％，优选约45％，并且以四羟黄酮糖苷表示的黄酮类的含量为2-5％，优选约2.5％。
菜豆提取物可使用商品化的提取物；但是，优选在PCT/EP2006/012012中所述的菜豆提取物。所述提取物是从菜豆(Phaseolus sp.)中用乙醇和水的混合物提取获得的，其特征在于α-淀粉酶抑制剂含量为1200-1600USP/mg(HPLC滴度为7-14％w/w)和植物凝集素含量为12,000-30,000HAU/g。所述提取物可以通过以下方法获得，该方法包括：
a)用pH值3-6.5的水性缓冲液提取菜豆，随后从生物量中分离提取物，其可以用缓冲液进一步提取，直到α-淀粉酶和植物凝集素抑制剂提取完为止；
b)将合并的提取物过滤或离心，浓缩至对应于离心后的最初提取物生物量的重量约10％的体积；
c)将浓缩的水提物用稀乙醇进行示差沉淀，至终浓度为60-70％v/v；
d)分离沉淀物，从去矿质水中用60％乙醇再沉淀或者用拦截10,000Da的膜进行渗滤，并且将沉淀残余物干燥。
比例为1∶0.25到1∶1的两种提取物的组合，包括每剂量为50-500mg、优选200mg的菜蓟提取物以及每剂量为50-200mg、优选100mg的菜豆提取物，在饭前服用或在食用富含碳水化合物的食物时服用。
本发明组合物的降血糖活性令人惊讶地优于两种成分各自单独的降血糖活性。按照Tormo MA等人，Br.J.Nutr.96，539，2006叙述的方法所得到的结果，显示在下表中。
表-纯化的菜蓟提取物、菜豆提取物以及它们的组合对以每日1小时限制进食的方式给予限制量的食物的Wistar大鼠血糖的影响
| 纯化的菜蓟提取物mg/kg口服 | 菜豆提取物mg/kg口服 | 血浆葡萄糖水平的AUC(mg/dL) |
| 0 | 0 | 30800±950 |
| 50 | 0 | 25100±700＊(-18％) |
| 0 | 50 | 27700±600(-10％) |
| 25 | 25 | 19800±800＊＊(-36％) |
每组动物数：8
＊p＜0.05 ＊＊p＜0.01，相对于对照
本发明的组合物适合于掺入药物制剂中，所述制剂如片剂、糖锭剂、软和硬明胶胶囊和纤维素胶囊。该提取物优选在富含多不饱和的ω3/ω6酸类的油中配制，例如月见草(Oenothera biennis)(夜来香)油。
已经在人类中以每天50-1000mg的剂量证实了与在实验动物中所观察到的相同结果。
下面的实施例用来对本发明作详细的说明。
实施例1-制备菜蓟刺状变种(Cynara scolymus vr.Spinosus)的提取物
将2kg在收获时被切碎和冷冻的菜蓟撒丁刺状变种(Cynara scolymusvr.Sardinian Spinosus)的花头装载于带有加热夹套的渗滤器中，用4760ml的95°EtOH覆盖，以得到约70％的醇含量(假定该植物中含水量为85％)。在70℃下保持接触3小时，随后卸载样品。在连续的提取中，用70％v/v的EtOH在70℃下覆盖植物进行萃取，最少的接触时间为3小时。共进行5次萃取，使用约15L的溶剂。
合并渗滤液并在35℃下真空浓缩，得到约15％的干燥残余物。
在环境温度下使之冷却，分离不溶的部分，将澄清的水溶液装载于填有530ml XAD-7HP树脂的柱子中。
洗涤柱子，先用530ml的水洗涤(除去洗脱液)，随后用1325ml的90％的EtOH洗涤。将含水的乙醇洗脱液浓缩，在50℃下真空干燥24小时。得到18.59g纯化的提取物。HPLC滴度：咖啡鞣酸49.13％、黄酮类2.68％。
实施例2-将菜蓟和菜豆提取物配制成用于软明胶胶囊的油状混悬液
单位组合物：
菜蓟提取物 100mg
菜豆提取物 100mg
单硬脂酸甘油酯 30mg
大豆卵磷脂 10mg
月见草油，适量以达到 700mg
制备方法
-加热月见草油至约70℃，并在搅拌下将单硬脂酸甘油酯在油中熔化。
-将大豆卵磷脂加入所得的溶液中。
-将菜蓟和菜豆的提取物分散在所得溶液中，确保其均匀分布。
-在保持搅拌的同时，逐渐使所得的溶液冷却。
实施例3-将菜蓟和菜豆提取物配制在硬明胶胶囊中
单位组合物：
菜蓟提取物 150mg
菜豆提取物 50mg
微晶纤维素 200mg
乳糖 95mg
二氧化硅 5mg
制备方法
-将提取物、微晶纤维素、乳糖和二氧化硅混合。
-把得到的混合物分装到硬明胶胶囊中。
实施例4-将菜蓟和菜豆提取物配制在缓释颗粒剂中
单位组合物
菜蓟提取物 100mg
菜豆提取物 50mg
微晶纤维素 100mg
聚维酮 10mg
羧甲基纤维素钠 8mg
甲基丙烯酸共聚物 50mg
柠檬酸三乙酯 3.2mg
滑石粉 8mg
西甲硅油 0.3mg
制备方法：
-用聚维酮的水溶液将提取物、微晶纤维素和羧甲基纤维素钠制粒。
-将所得的颗粒干燥和标定。
-用甲基丙烯酸共聚物、柠檬酸三乙酯、滑石粉和西甲硅油的水性混悬液对颗粒进行包衣。
实施例5-将菜蓟和菜豆提取物配制在速释颗粒剂中
单位组合物：
菜蓟提取物 100mg
菜豆提取物 50mg
微晶纤维素 100mg
聚维酮 10mg
羧甲基纤维素钠 8mg
制备方法：
-用聚维酮的水溶液将提取物、微晶纤维素和羧甲基纤维素钠制粒。
-将所得的颗粒干燥和标定。
实施例6-具有不同释放特性的菜蓟和菜豆提取物的颗粒混合物
制备方法：
-将50％的实施例4所述的颗粒与50％的实施例5所述的颗粒相混合。
-将所得的混合物分装到硬明胶胶囊中。
Claims (5)
1.包含比例为1∶0.25到1∶1的菜蓟提取物和菜豆提取物的组合物。
2.如权利要求1所述的组合物，其中菜蓟提取物具有的咖啡鞣酸含量为30-60％，四羟黄酮糖苷含量为2-5％。
3.如权利要求1或2所述的组合物，其中菜豆提取物的特征在于α-淀粉酶抑制剂含量为1200-1600USP/mg(HPLC滴度为7-14％w/w)和植物凝集素含量为12,000-30,000HAU/g。
4.如权利要求1-3中任一项所述的组合物，其还含有月见草油。
5.如权利要求1-4中所述的制剂在制备具有降血糖和抗肥胖作用的药物中的用途。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90532007P | 2007-03-07 | 2007-03-07 | |
| EP07425132A EP1967198B1 (en) | 2007-03-07 | 2007-03-07 | Formulations containing cynara scolymus and phaseolus vulgaris extracts which are useful in the treatment of obesity |
| US60/905,320 | 2007-03-07 | ||
| EP07425132.3 | 2007-03-07 | ||
| PCT/EP2008/001787 WO2008107184A1 (en) | 2007-03-07 | 2008-03-06 | Formulations containing cynara scolymus and phaseolus vulgaris extracts which are useful in the treatment of obesity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101641111A true CN101641111A (zh) | 2010-02-03 |
| CN101641111B CN101641111B (zh) | 2012-05-23 |
Family
ID=38229761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200880007206XA Expired - Fee Related CN101641111B (zh) | 2007-03-07 | 2008-03-06 | 包含用于治疗肥胖症的菜蓟与菜豆提取物的制剂 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US7887854B2 (zh) |
| EP (1) | EP1967198B1 (zh) |
| JP (1) | JP5355424B2 (zh) |
| KR (1) | KR101456555B1 (zh) |
| CN (1) | CN101641111B (zh) |
| AT (1) | ATE431155T1 (zh) |
| AU (1) | AU2008224057B2 (zh) |
| BR (1) | BRPI0808563B1 (zh) |
| CA (1) | CA2680078C (zh) |
| DE (1) | DE602007001128D1 (zh) |
| DK (1) | DK1967198T3 (zh) |
| ES (1) | ES2323815T3 (zh) |
| HK (1) | HK1121694A1 (zh) |
| IL (1) | IL200709A (zh) |
| NO (1) | NO339322B1 (zh) |
| PL (1) | PL1967198T3 (zh) |
| PT (1) | PT1967198E (zh) |
| RU (1) | RU2453323C2 (zh) |
| SI (1) | SI1967198T1 (zh) |
| WO (1) | WO2008107184A1 (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104703616A (zh) * | 2012-10-12 | 2015-06-10 | 因德纳有限公司 | 治疗和预防肥胖的制剂 |
| CN110433280A (zh) * | 2019-09-11 | 2019-11-12 | 周口师范学院 | 植物血凝素在制备预防或治疗肥胖药物中的应用 |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20052450A1 (it) | 2005-12-22 | 2007-06-23 | Indena Spa | Estratti di phaseolus vulgaris loro uso e formulazioni che li contengono |
| CN101874822A (zh) | 2009-04-27 | 2010-11-03 | 玫琳凯有限公司 | 植物性抗痤疮制剂 |
| EP2345646A1 (en) * | 2010-01-14 | 2011-07-20 | InterMed Discovery GmbH | Use of tricyclic sesquiterpene lactones in the treatment of obesity and related diseases and non-therapeutic treatable conditions |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| KR101330190B1 (ko) | 2011-09-20 | 2013-11-15 | (주)그린솔루션스 | 하고초 추출물의 헴 옥시게나아제-1 발현 조절을 통한 지방 생성 억제용 화장료 조성물 |
| KR102245069B1 (ko) | 2011-12-19 | 2021-04-26 | 마리 케이 인코포레이티드 | 피부톤 향상을 위한 식물 추출물의 조합물 |
| ITMI20121570A1 (it) * | 2012-09-20 | 2014-03-21 | Indena Spa | Nuovi estratti di cynara scolimus, coffea spp. e olea europaea per il trattamento della sindrome metabolica |
| ITMI20121749A1 (it) * | 2012-10-16 | 2014-04-17 | Indena Spa | Estratti di helianthus annuus utili nel trattamento della sindrome metabolica e nella diminuzione dell'indice glicemico di alimenti e procedimento per la loro preparazione e composizioni che li contengono |
| KR102323049B1 (ko) | 2014-03-10 | 2021-11-05 | 마리 케이 인코포레이티드 | 피부 라이트닝 조성물 |
| DE202014005450U1 (de) * | 2014-07-04 | 2015-10-06 | Ursapharm Arzneimittel Gmbh | Lactosefreies Arzneimittel |
| US20160302451A1 (en) * | 2015-04-16 | 2016-10-20 | Michael Hudnall | Medical Food for Patients with Chronic Liver Disease |
| FR3075570B1 (fr) * | 2017-12-22 | 2020-01-03 | Agro Innovation International | Stimulation de la nitrification d'un sol avec des compositions comprenant un extrait de plante |
| IT201900000367A1 (it) * | 2019-01-10 | 2020-07-10 | Altergon Sa | Composizioni comprendenti un peptide in grado di stimolare la via del segnale gprc6a-dipendente |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8524275D0 (en) * | 1985-10-02 | 1985-11-06 | Efamol Ltd | Pharmaceutical & dietary compositions |
| DE19627376A1 (de) * | 1996-07-06 | 1998-01-08 | Aar Pharma Adler Apotheke | Verwendung von Artischocken-(Cynara)-Extrakten |
| HRP990080B1 (en) * | 1999-03-12 | 2003-04-30 | Vladimir Leko | Plant mixture and a medical preparation for the treatment of diabetes mellitus, type ii, obtained therefrom |
| US6818234B1 (en) * | 1999-08-27 | 2004-11-16 | Access Business Group International Llc | Dietary food supplement containing natural cyclooxygenase inhibitors and methods for inhibiting pain and inflammation |
| ITMI20051347A1 (it) | 2005-07-14 | 2007-01-15 | Indena Spa | Estratti di cynara scolimus loro uso e formulazioni che li contengono |
| ITMI20052450A1 (it) | 2005-12-22 | 2007-06-23 | Indena Spa | Estratti di phaseolus vulgaris loro uso e formulazioni che li contengono |
-
2007
- 2007-03-07 ES ES07425132T patent/ES2323815T3/es active Active
- 2007-03-07 PL PL07425132T patent/PL1967198T3/pl unknown
- 2007-03-07 AT AT07425132T patent/ATE431155T1/de active
- 2007-03-07 DE DE602007001128T patent/DE602007001128D1/de active Active
- 2007-03-07 SI SI200730037T patent/SI1967198T1/sl unknown
- 2007-03-07 DK DK07425132T patent/DK1967198T3/da active
- 2007-03-07 EP EP07425132A patent/EP1967198B1/en active Active
- 2007-03-07 PT PT07425132T patent/PT1967198E/pt unknown
-
2008
- 2008-03-05 US US12/042,354 patent/US7887854B2/en active Active
- 2008-03-06 US US12/529,990 patent/US7887855B2/en active Active
- 2008-03-06 BR BRPI0808563-3A patent/BRPI0808563B1/pt not_active IP Right Cessation
- 2008-03-06 RU RU2009133338/15A patent/RU2453323C2/ru active
- 2008-03-06 CA CA2680078A patent/CA2680078C/en active Active
- 2008-03-06 AU AU2008224057A patent/AU2008224057B2/en not_active Ceased
- 2008-03-06 WO PCT/EP2008/001787 patent/WO2008107184A1/en active Application Filing
- 2008-03-06 CN CN200880007206XA patent/CN101641111B/zh not_active Expired - Fee Related
- 2008-03-06 KR KR1020097018545A patent/KR101456555B1/ko active IP Right Grant
- 2008-03-06 JP JP2009552122A patent/JP5355424B2/ja not_active Expired - Fee Related
-
2009
- 2009-02-26 HK HK09101867.9A patent/HK1121694A1/xx not_active IP Right Cessation
- 2009-09-03 IL IL200709A patent/IL200709A/en active IP Right Grant
-
2010
- 2010-04-14 NO NO20100527A patent/NO339322B1/no not_active IP Right Cessation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104703616A (zh) * | 2012-10-12 | 2015-06-10 | 因德纳有限公司 | 治疗和预防肥胖的制剂 |
| CN110433280A (zh) * | 2019-09-11 | 2019-11-12 | 周口师范学院 | 植物血凝素在制备预防或治疗肥胖药物中的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20080220097A1 (en) | 2008-09-11 |
| WO2008107184A1 (en) | 2008-09-12 |
| AU2008224057B2 (en) | 2012-07-19 |
| PT1967198E (pt) | 2009-06-15 |
| NO339322B1 (no) | 2016-11-28 |
| EP1967198A1 (en) | 2008-09-10 |
| EP1967198B1 (en) | 2009-05-13 |
| US20100136145A1 (en) | 2010-06-03 |
| DK1967198T3 (da) | 2009-08-10 |
| IL200709A (en) | 2013-07-31 |
| JP5355424B2 (ja) | 2013-11-27 |
| RU2009133338A (ru) | 2011-03-10 |
| US7887854B2 (en) | 2011-02-15 |
| RU2453323C2 (ru) | 2012-06-20 |
| DE602007001128D1 (de) | 2009-06-25 |
| KR20090118051A (ko) | 2009-11-17 |
| CN101641111B (zh) | 2012-05-23 |
| JP2010520246A (ja) | 2010-06-10 |
| US7887855B2 (en) | 2011-02-15 |
| HK1121694A1 (en) | 2009-04-30 |
| KR101456555B1 (ko) | 2014-10-31 |
| BRPI0808563A2 (pt) | 2014-09-02 |
| PL1967198T3 (pl) | 2009-10-30 |
| ES2323815T3 (es) | 2009-07-24 |
| IL200709A0 (en) | 2010-05-17 |
| CA2680078A1 (en) | 2008-09-12 |
| BRPI0808563B1 (pt) | 2018-02-14 |
| SI1967198T1 (sl) | 2009-08-31 |
| NO20100527A1 (no) | 2010-05-19 |
| ATE431155T1 (de) | 2009-05-15 |
| AU2008224057A1 (en) | 2008-09-12 |
| CA2680078C (en) | 2016-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101641111B (zh) | 包含用于治疗肥胖症的菜蓟与菜豆提取物的制剂 | |
| JP2013501778A (ja) | チアシード及びマカを含む健康補助食品、飼料、薬学組成物並びにその製造方法 | |
| US20060198907A1 (en) | Pharmaceutical, therapeutic, and dietary compositions derived from Lagerstroemia speciosa L. plant | |
| WO2008107183A1 (en) | Cynara scolymus extracts and compositions containing them | |
| JP2006347967A (ja) | 血糖値上昇抑制剤 | |
| JP2015535216A (ja) | ヒマワリからカフェオイルキナ酸に富んだ抽出物を得る方法 | |
| CN105535152B (zh) | 一种枇杷叶总倍半萜苷提取物的应用 | |
| WO2021174801A1 (zh) | 一种牛樟芝水不溶性膳食纤维的制备方法 | |
| CA2570989A1 (en) | Product of vegetal origin comprising proanthocyanidines and its preparation process | |
| CN112655967A (zh) | 一种以马齿苋提取物为壁材的大籽蒿精油微胶囊及其制备方法 | |
| WO2021020210A1 (ja) | 腸内細菌叢調整剤 | |
| JP4610730B2 (ja) | カルシウム補給用の組成物 | |
| EP1673985A1 (en) | Functional sweetener | |
| JP2006022033A (ja) | 血管新生抑制剤 | |
| JP3183758B2 (ja) | 血中中性脂肪改善剤及びその製造方法並びにこれを含有する組成物 | |
| JP2010285357A (ja) | 酒粕由来の抗酸化成分の製造方法 | |
| KR20090118050A (ko) | 시나라 스콜리무스 추출물 및 그를 포함하는 조성물 | |
| CN118845914A (zh) | 含沉香叶的降血脂组合物及其制备方法和用途、保健食品 | |
| CN118620098A (zh) | 一种刺梨多糖用于制备抗血管钙化的药物的用途 | |
| JP2024018368A (ja) | 腸内細菌叢改善用組成物 | |
| CN103919766A (zh) | 一种降低尿蛋白的药物组合物及其应用 | |
| JP2021000055A (ja) | サラシア属植物の抽出物を含有する経口組成物 | |
| KR20130048584A (ko) | 수리취 식이섬유를 포함하는 변비 개선용 조성물 | |
| KR20140123263A (ko) | 토끼풀 추출물을 유효성분으로 함유하는 비만 또는 대사증후군 관련 질환의 예방 및 개선용 조성물 | |
| JP2014136699A (ja) | Ｃｅｐａｔｈｉｏｌａｎｅｓを有効成分とする脂質代謝改善用組成物、及び食品添加剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120523 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |